Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
ClinicalTrials.gov study NCT04014075. IPD Sharing: YES. Countries: 5. Publications: 2.
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
ClinicalTrials.gov study NCT03329690. IPD Sharing: YES. Countries: 2. Publications: 2.
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT04744831. IPD Sharing: YES. Countries: 10. Publications: 2.
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03505710. IPD Sharing: YES. Countries: 5. Publications: 3.
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibito
ClinicalTrials.gov study NCT01610284. IPD Sharing: YES. Countries: 29. Publications: 2.
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
ClinicalTrials.gov study NCT00680901. IPD Sharing: YES. Countries: 23. Publications: 2.
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
ClinicalTrials.gov study NCT03384940. IPD Sharing: YES. Countries: 5. Publications: 3.
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
ClinicalTrials.gov study NCT02278120. IPD Sharing: YES. Countries: 30. Publications: 10.
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
ClinicalTrials.gov study NCT01953926. IPD Sharing: YES. Countries: 13. Publications: 10.
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
ClinicalTrials.gov study NCT01633060. IPD Sharing: UNDECIDED. Countries: 22. Publications: 1.
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
ClinicalTrials.gov study NCT03789110. IPD Sharing: YES. Countries: 1. Publications: 1.
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progres
ClinicalTrials.gov study NCT03056755. IPD Sharing: YES. Countries: 19. Publications: 4.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00876395. IPD Sharing: UNDECIDED. Countries: 28. Publications: 3.
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
ClinicalTrials.gov study NCT02941926. IPD Sharing: YES. Countries: 38. Publications: 5.
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative L
ClinicalTrials.gov study NCT04576455. IPD Sharing: YES. Countries: 17. Publications: 2.
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT01937117. IPD Sharing: NO. Countries: 1. Publications: 2.
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
ClinicalTrials.gov study NCT04704934. IPD Sharing: YES. Countries: 24. Publications: 1.
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
ClinicalTrials.gov study NCT03043313. IPD Sharing: Not stated. Countries: 5. Publications: 4.
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
ClinicalTrials.gov study NCT02927249. IPD Sharing: Not stated. Countries: 4. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.